Innate Pharma S.A (IPH) | Stock Overview & Key Data
Innate Pharma S.A. | Small-cap | Healthcare
Innate Pharma S.A. | Small-cap | Healthcare
Innate Pharma S.A Performance Comparison
Stock Range
Today's Range
Low: €1.58
High: €1.74
on July 18, 2025
52 Week Range
Low: €1.33
High: €2.50
on December 2, 2024
on February 18, 2025
All-Time High: €17.85 on April 20, 2015
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€145.6M
EPS
-0.61
P/E Ratio (TTM)
-2.59
Forward P/E
1.17
P/B Ratio
15.05
PEG Ratio
0.00
Div. Yield
N/A
ROE
-162.91%
Beta
0.984
Debt to Equity
350.86
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-324.87%
Profit Margin
-245.87%
Returns and Earnings
Return on Assets (TTM)
-22.52%
Return on Equity (TTM)
-162.91%
EBITDA
€-50.3M
Net Income (TTM)
€-49.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.24
Quarterly Revenue Growth (YoY)
-63.70%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Innate Pharma S.A IPH | 145.62M Small-cap | 14.67% | 3.61% | 0.00% | -0.58% | -8.99% | -16.10% | -41.69% | -68.61% |
| Medincell S.A MEDCL | 557.56M Mid-cap | -0.25% | -2.79% | 10.57% | -1.36% | -8.78% | 4.03% | 214.96% | 103.05% |
| Abivax SA ABVX | 547.13M Mid-cap | 21.24% | 62.95% | 60.52% | 37.92% | 18.41% | -25.95% | 2.86% | -60.64% |
| Ose OSE | 120.48M Small-cap | 4.93% | 4.52% | -5.84% | -18.78% | -29.35% | -19.03% | -19.27% | -9.83% |
| Sensorion SA ALSEN | 106.99M Small-cap | 6.45% | -13.16% | 94.12% | -50.00% | -48.44% | -50.75% | -19.51% | -70.54% |
| Transgene S.A TNG | 110.78M Small-cap | -1.27% | -16.13% | 30.00% | 11.43% | 14.71% | -30.36% | -66.67% | -49.02% |
Ownership & Short Interest
Insider Ownership
31.04%
Institutional Ownership
10.09%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
138K
Average 90-Day Volume
132K
Innate Pharma S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Innate Pharma S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is IPH's 52-week high and low?
- In the last 52 weeks, Innate Pharma S.A reached a high of €2.50 (on February 18, 2025) and a low of €1.33 (on December 2, 2024).
- What is the market cap and P/E ratio for IPH?
- Curious about Innate Pharma S.A's size and valuation? Its market capitalization stands at 145.62M. When it comes to valuation, the P/E ratio (trailing twelve months) is -2.59, and the forward P/E (looking ahead) is 1.17.
- Does IPH pay dividends? If so, what's the yield?
- As for dividends, Innate Pharma S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Innate Pharma S.A's main competitors or similar companies to consider before investing?
When looking at Innate Pharma S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Medincell S.A
MEDCL557.56M Healthcare Biotechnology 4.03% 214.96% Abivax SA
ABVX547.13M Healthcare Biotechnology -25.95% 2.86% Ose
OSE120.48M Healthcare Biotechnology -19.03% -19.27% Sensorion SA
ALSEN106.99M Healthcare Biotechnology -50.75% -19.51% Transgene S.A
TNG110.78M Healthcare Biotechnology -30.36% -66.67% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Innate Pharma S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Innate Pharma S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -162.91%, the Debt to Equity ratio from the most recent quarter is 350.86, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for IPH?
- Looking at Innate Pharma S.A's growth, its revenue over the trailing twelve months (TTM) was €20M. Compared to the same quarter last year (YoY), quarterly revenue grew by -63.70%, and quarterly earnings saw a YoY growth of N/A.
- How much of IPH stock is held by insiders and institutions?
- Wondering who owns Innate Pharma S.A stock? Company insiders (like executives and directors) hold about 31.04% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 10.09%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.